Phase 2 Trial Seeking Patients for Zejula-Avastin Combo as Maintenance Therapy for Advanced Ovarian Cancer

Phase 2 Trial Seeking Patients for Zejula-Avastin Combo as Maintenance Therapy for Advanced Ovarian Cancer
Tesaro is recruiting for its Phase 2 trial testing its therapy Zejula (niraparib) plus Avastin (bevacizumab, Genentech) as a maintenance therapy for women with advanced ovarian cancer who achieved at least a partial response after platinum-based chemotherapy plus Avastin. The study — called OVARIO (NCT03326193) — is looking for 90 patients, regardless of their BRCA mutation or homologous

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *